Lv J, Zhao HP, Yu Y, Wang JH, Zhang XJ, Guo ZQ, Jiang WY, Wang K, Guo L. From gut microbial ecology to lipid homeostasis: Decoding the role of gut microbiota in dyslipidemia pathogenesis and intervention. World J Gastroenterol 2025; 31(30): 108680 [DOI: 10.3748/wjg.v31.i30.108680]
Corresponding Author of This Article
Lei Guo, MD, Department of Spine Surgery, Honghui Hospital, Xi’an Jiaotong University, No. 555 Youyi East Road, Xi’an 710054, Shaanxi Province, China. guolei0711@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Aug 14, 2025; 31(30): 108680 Published online Aug 14, 2025. doi: 10.3748/wjg.v31.i30.108680
From gut microbial ecology to lipid homeostasis: Decoding the role of gut microbiota in dyslipidemia pathogenesis and intervention
Jing Lv, He-Ping Zhao, Yan Yu, Ji-Han Wang, Xiao-Jun Zhang, Zhi-Qi Guo, Wen-Yan Jiang, Kai Wang, Lei Guo
Jing Lv, He-Ping Zhao, Yan Yu, Xiao-Jun Zhang, Zhi-Qi Guo, Wen-Yan Jiang, Kai Wang, Department of Clinical Laboratory, Honghui Hospital, Xi’an Jiaotong University, Xi’an 710054, Shaanxi Province, China
Ji-Han Wang, Yan’an Medical College, Yan’an University, Yan’an 716000, Shaanxi Province, China
Lei Guo, Department of Spine Surgery, Honghui Hospital, Xi’an Jiaotong University, Xi’an 710054, Shaanxi Province, China
Co-first authors: Jing Lv and He-Ping Zhao.
Author contributions: Lv J and Zhao HP contributed equally to this work, Lv J and Zhao HP are co-first authors of this manuscript; Lv J and Guo L conceptualized and designed the study, searched and reviewed published articles, and wrote the original manuscript; Zhao HP, Yu Y, Wang JH, Zhang XJ, Guo ZQ, Jiang WY, and Wang K conducted online data search, and critically reviewed the original manuscript; Lv J and Zhang XJ constructed figures presented in this manuscript. All authors approved the submitted version.
Supported by Shaanxi Natural Science Foundation of China, No. 2025JC-YBMS-916; and Xi’an Municipal Health Commission of China, No. 2023ms11.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Lei Guo, MD, Department of Spine Surgery, Honghui Hospital, Xi’an Jiaotong University, No. 555 Youyi East Road, Xi’an 710054, Shaanxi Province, China. guolei0711@163.com
Received: May 6, 2025 Revised: June 16, 2025 Accepted: July 16, 2025 Published online: August 14, 2025 Processing time: 98 Days and 22.5 Hours
Core Tip
Core Tip: Dyslipidemia’s multifactorial pathogenesis involves gene-environment-microbiota crosstalk, with gut microbiota (GM) emerging as a master regulator of lipid homeostasis through lipopolysaccharide-induced very low-density lipoprotein overproduction, short-chain fatty acid-G protein-coupled receptor signaling, bile acid-farnesoid X receptor/Takeda G protein-coupled receptor 5 axis modulation, and microbiota-host non-coding RNA crosstalk. This review delineates GM-dyslipidemia interactions, molecular mechanisms, and interventions such as probiotics, prebiotics and fecal microbiota transplantation. Key challenges involve establishing causal GM-lipid pathway links and optimal intervention timing. Advancing precision therapies require longitudinal multi-omics integration coupled with gnotobiotic validation models, ultimately enabling machine learning-driven prediction of personalized microbial signatures for targeted cardiovascular prevention.